| Literature DB >> 31155052 |
Sam Lear1, Zaid Amso1, Weijun Shen2.
Abstract
G protein-coupled receptors (GPCRs) play a key role in signal transduction and human pathophysiological processes. Family B GPCRs are activated by a number of secreted peptide hormones, and engineering of these peptide ligands in order to improve stability and half-life, and therefore clinical efficacy has proven successful for drug discovery. In this chapter we discuss a novel peptide engineering strategy that combines peptide side chain stapling with covalent incorporation of a serum protein binding motif in a single step. The application of this approach to the enhancement of the helicity and stability of GLP-1R peptide agonists, resulting in their improved in vitro potencies, in vivo half-lives and ultimately efficacies, will be described. Discussion of the stapling technology and target selection rationale, peptide engineering and final biological characterization of the long-acting agonists will also be provided.Entities:
Keywords: Diabetes; Exenatide; GLP-1; GPCR; Lipid-drug conjugate; Long-acting; Obesity; Peptide stapling; Prolonged half-life; Serum protein binding
Mesh:
Substances:
Year: 2019 PMID: 31155052 DOI: 10.1016/bs.mie.2019.02.008
Source DB: PubMed Journal: Methods Enzymol ISSN: 0076-6879 Impact factor: 1.600